If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Lyumjev™ (insulin lispro – aabc) injection
100 units/mL, 200 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
LYUMJEV™ (insulin lispro-aabc): Marketing Approval
The approval of URLi by the US FDA was communicated on June 15, 2020. URLi is approved for the treatment of adults with diabetes.
The approval of URLi for the treatment of adults with T1DM or T2DM was communicated by FDA on June 15, 2020. URLi is marketed under the brand name Lyumjev™ (insulin lispro-aabc) injection.1
Enclosed Prescribing Information
LYUMJEV™ (insulin lispro-aabc) injection, for subcutaneous or intravenous use, Lilly
1. FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin. Press release. Eli Lilly and Company; June 15, 2020. Accessed July 3, 2020. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lyumjevtm-insulin-lispro-aabc-injection-lillys-new
Glossary
Lilly = Eli Lilly and Company
T1DM = type 1 diabetes mellitus
T2DM = type 2 diabetes mellitus
URLi = Lyumjev™ (insulin lispro-aabc)
Date of Last Review: July 03, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
